342 related articles for article (PubMed ID: 11073824)
21. Characteristic matrix and tubular basement membrane abnormalities in the CBA/Ca-kdkd mouse model of hereditary tubulointerstitial disease.
Sibalic V; Sun L; Sibalic A; Oertli B; Ritthaler T; Wüthrich RP
Nephron; 1998 Nov; 80(3):305-13. PubMed ID: 9807040
[TBL] [Abstract][Full Text] [Related]
22. Lysyl oxidase like-2 contributes to renal fibrosis in Col4α3/Alport mice.
Cosgrove D; Dufek B; Meehan DT; Delimont D; Hartnett M; Samuelson G; Gratton MA; Phillips G; MacKenna DA; Bain G
Kidney Int; 2018 Aug; 94(2):303-314. PubMed ID: 29759420
[TBL] [Abstract][Full Text] [Related]
23. Albumin contributes to kidney disease progression in Alport syndrome.
Jarad G; Knutsen RH; Mecham RP; Miner JH
Am J Physiol Renal Physiol; 2016 Jul; 311(1):F120-30. PubMed ID: 27147675
[TBL] [Abstract][Full Text] [Related]
24. Monocytes may promote myofibroblast accumulation and apoptosis in Alport renal fibrosis.
Rodgers KD; Rao V; Meehan DT; Fager N; Gotwals P; Ryan ST; Koteliansky V; Nemori R; Cosgrove D
Kidney Int; 2003 Apr; 63(4):1338-55. PubMed ID: 12631350
[TBL] [Abstract][Full Text] [Related]
25. Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-beta1-induced kidney disease.
Krag S; Danielsen CC; Carmeliet P; Nyengaard J; Wogensen L
Kidney Int; 2005 Dec; 68(6):2651-66. PubMed ID: 16316341
[TBL] [Abstract][Full Text] [Related]
26. Transforming growth factor beta1-induced glomerulopathy is prevented by 17beta-estradiol supplementation.
Birch Nielsen C; Krag S; ØSterby R; Flyvbjerg A; Nyengaard J; Forman A; Wogensen L
Virchows Arch; 2004 Jun; 444(6):561-6. PubMed ID: 15107991
[TBL] [Abstract][Full Text] [Related]
27. Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease.
Gross O; Girgert R; Beirowski B; Kretzler M; Kang HG; Kruegel J; Miosge N; Busse AC; Segerer S; Vogel WF; Müller GA; Weber M
Matrix Biol; 2010 Jun; 29(5):346-56. PubMed ID: 20307660
[TBL] [Abstract][Full Text] [Related]
28. TGF-beta1-induced glomerular disorder is associated with impaired concentrating ability mimicking primary glomerular disease with renal failure in man.
Krag S; Osterby R; Chai Q; Nielsen CB; Hermans C; Wogensen L
Lab Invest; 2000 Dec; 80(12):1855-68. PubMed ID: 11140698
[TBL] [Abstract][Full Text] [Related]
29. Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis.
Mitrofanova A; Molina J; Varona Santos J; Guzman J; Morales XA; Ducasa GM; Bryn J; Sloan A; Volosenco I; Kim JJ; Ge M; Mallela SK; Kretzler M; Eddy S; Martini S; Wahl P; Pastori S; Mendez AJ; Burke GW; Merscher S; Fornoni A
Kidney Int; 2018 Dec; 94(6):1151-1159. PubMed ID: 30301568
[TBL] [Abstract][Full Text] [Related]
30. Dynamic expression patterns of transforming growth factor-beta(2) and transforming growth factor-beta receptors in experimental glomerulonephritis.
Hartner A; Hilgers KF; Bitzer M; Veelken R; Schöcklmann HO
J Mol Med (Berl); 2003 Jan; 81(1):32-42. PubMed ID: 12545247
[TBL] [Abstract][Full Text] [Related]
31. mRNA expression of glomerular basement membrane proteins and TGF-beta1 in human membranous nephropathy.
Kim TS; Kim JY; Hong HK; Lee HS
J Pathol; 1999 Nov; 189(3):425-30. PubMed ID: 10547606
[TBL] [Abstract][Full Text] [Related]
32. Chronic renal failure and shortened lifespan in COL4A3+/- mice: an animal model for thin basement membrane nephropathy.
Beirowski B; Weber M; Gross O
J Am Soc Nephrol; 2006 Jul; 17(7):1986-94. PubMed ID: 16775036
[TBL] [Abstract][Full Text] [Related]
33. Transforming growth factor-beta (TGF-beta) stimulates the expression of beta1 integrins and adhesion by rat mesangial cells.
Kagami S; Kuhara T; Yasutomo K; Okada K; Löster K; Reutter W; Kuroda Y
Exp Cell Res; 1996 Nov; 229(1):1-6. PubMed ID: 8940242
[TBL] [Abstract][Full Text] [Related]
34. Transforming growth factor-beta receptors in self-limited vs. chronic progressive nephritis in rats.
Watanabe T; Yamamoto T; Ikegaya N; Fujigaki Y; Suzuki H; Togawa A; Fukasawa H; Nagase M; Hishida A
J Pathol; 2002 Nov; 198(3):397-406. PubMed ID: 12375273
[TBL] [Abstract][Full Text] [Related]
35. Collagen IV diseases: A focus on the glomerular basement membrane in Alport syndrome.
Cosgrove D; Liu S
Matrix Biol; 2017 Jan; 57-58():45-54. PubMed ID: 27576055
[TBL] [Abstract][Full Text] [Related]
36. [Alport syndrome: Hereditary nephropathy associated with mutations in genes coding for type IV collagen chains].
Heidet L; Gubler MC
Nephrol Ther; 2016 Dec; 12(7):544-551. PubMed ID: 27816395
[TBL] [Abstract][Full Text] [Related]
37. Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome.
Cosgrove D; Meehan DT; Grunkemeyer JA; Kornak JM; Sayers R; Hunter WJ; Samuelson GC
Genes Dev; 1996 Dec; 10(23):2981-92. PubMed ID: 8956999
[TBL] [Abstract][Full Text] [Related]
38. Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome.
Koepke ML; Weber M; Schulze-Lohoff E; Beirowski B; Segerer S; Gross O
Nephrol Dial Transplant; 2007 Apr; 22(4):1062-9. PubMed ID: 17287218
[TBL] [Abstract][Full Text] [Related]
39. Alpha8 integrin in glomerular mesangial cells and in experimental glomerulonephritis.
Hartner A; Schöcklmann H; Pröls F; Müller U; Sterzel RB
Kidney Int; 1999 Oct; 56(4):1468-80. PubMed ID: 10504498
[TBL] [Abstract][Full Text] [Related]
40. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria.
Wang A; Ziyadeh FN; Lee EY; Pyagay PE; Sung SH; Sheardown SA; Laping NJ; Chen S
Am J Physiol Renal Physiol; 2007 Nov; 293(5):F1657-65. PubMed ID: 17804483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
